Filing Flows › Fulgent Genetics (FLGT) › Q2 2026 › vs Q1 2026
Fulgent Genetics (FLGT) Q2 2026 vs Q1 2026 (quarter over quarter)
Fulgent Genetics's revenue rose $14.3M (+20%) from $71.1M in Q1 2026 to $85.4M in Q2 2026. The biggest changes: Laboratory Services +$14.3M (+20%); Therapeutic Development −$57K (-66%).
Fulgent Genetics, Q2 2026: revenue $85.4M (+4% year over year), operating margin -42.2%, net loss $29.7M, operating cash flow −$23.8M. The chart draws each line against Q1 2026, the increases inside each band.
Every line
| Line | Q2 2026 | Q1 2026 | Change | % |
|---|---|---|---|---|
| Laboratory Services | $85.4M | $71.1M | $14.3M | +20% |
| Therapeutic Development | $30K | $87K | −$57K | -66% |
| Revenue | $85.4M | $71.1M | $14.3M | +20% |
| Other income, net | $6.4M | $8.6M | −$2.3M | -26% |
| Net loss | $29.7M | $25.3M | $4.4M | +18% |
| Costs & expenses | $121M | $106M | $15.7M | +15% |
| Operating costs | $121M | $106M | $15.7M | +15% |
| Income tax | $29K | −$704K | $733K | — |
| Cost of revenue | $59.7M | $49.6M | $10.1M | +20% |
| Research & development | $14.6M | $14.2M | $378K | +3% |
| Sales & marketing | $15.2M | $12.2M | $3.0M | +25% |
| General & admin | $27.2M | $27.7M | −$489K | -2% |
| Other operating costs | $4.8M | $2.0M | $2.7M | +135% |
| Operating cash sources | $40.1M | $8.8M | $31.3M | +356% |
| Depreciation & amortization | $7.7M | $6.0M | $1.7M | +28% |
| Share-based compensation | $8.6M | $9.9M | −$1.3M | -13% |
| Cash used in operations | $23.8M | −$7.1M | $30.9M | — |
| Net loss absorbed | $29.7M | $25.3M | $4.4M | +18% |
| Working capital & other | $10.3M | −$16.5M | $26.8M | — |
Questions
How much did Fulgent Genetics's revenue grow quarter over quarter in Q2 2026?
Fulgent Genetics's revenue rose $14.3M (+20%) from $71.1M in Q1 2026 to $85.4M in Q2 2026.
What drove Fulgent Genetics's revenue change in Q2 2026?
Laboratory Services +$14.3M (+20%); Therapeutic Development −$57K (-66%).